AUS
NZ
UK
CA
USA
IND
CurveBeam AI Limited (ASX:CVB) is set to hold a general meeting on 21 August 2026 to obtain shareholder consent for a $5 million capital raise via share placement to multiple investors, including strategic partner Intellivision Holdings Pte. Ltd and related parties. The company, specializing in AI-driven musculoskeletal imaging technology, requires approval of four interdependent resolutions. Failure to pass all will halt the placement, potentially jeopardizing CurveBeam AI’s ability to fulfill financial obligations due in October 2027.
Key Points
- CurveBeam AI Limited (CVB) will conduct a virtual general meeting on Friday, 21 August 2026 at 09:00am AEST
- Shareholders will vote on four interconditional resolutions to approve a $5 million equity placement priced at $0.02 per share
- The placement involves issuing 130 million shares to Intellivision Holdings Pte. Ltd, 2.5 million shares to Lan Gao, 15 million shares to trustees Gregory Wayne Brown and Stefanie Brown, and 102.5 million shares to Arun Singh and Susmita Singh
- The company seeks ratification of a prior share issue of 9,876,543 shares to Shandong WeiYing Intelligent Medical Technology Co., Ltd under ASX Listing Rule 7.1A
- If the resolutions fail, CurveBeam AI may lack funds to repay a $2.05 million director loan due October 2027 and to sustain operations
Overview of CurveBeam AI’s $5 Million Capital Raise and Placement Structure
CurveBeam AI Limited has announced plans to raise $5 million through an equity placement at $0.02 per share, divided into four separate tranches. Each tranche requires shareholder approval via interconditional resolutions, meaning all four must be approved collectively for the capital raise to proceed. If any resolution fails, the entire $5 million placement will be void.
The capital raise aims to support CurveBeam AI’s operational and strategic initiatives in the AI-powered musculoskeletal imaging sector. This structured approach broadens the investor base while preserving strategic partnerships. The interconditional resolutions safeguard shareholders by preventing partial or fragmented capital injections.
Intellivision Holdings’ Cornerstone Investment in Placement
The largest tranche involves Intellivision Holdings Pte. Ltd acquiring 130 million shares under Resolution 1, forming the cornerstone of the capital raise. This investment highlights a significant strategic alliance between CurveBeam AI and the Singapore-based investor. All placement shares are priced uniformly at $0.02, ensuring consistent valuation.
Intellivision Holdings’ participation validates CurveBeam AI’s business model and AI technology platform within the competitive musculoskeletal imaging market. Their commitment, subject to shareholder approval, underscores strong institutional confidence. The placement complies with ASX Listing Rule 7.1, governing equity issuances by listed entities.
Related Party Share Allocations Under Resolutions 3 and 4
Related parties Arun Singh and Susmita Singh will receive 102.5 million shares under Resolution 4, the largest related party tranche. Trustees Gregory Wayne Brown and Stefanie Brown will receive 15 million shares under Resolution 3. These transactions require approval under ASX Listing Rule 10.11, addressing related party and director dealings.
Combined, related party allocations total 117.5 million shares, a significant portion of the placement. The interconditional resolutions ensure shareholders consider the entire related party framework collectively, enhancing transparency and governance regarding potential conflicts.
Participation of Individual Investor Lan Gao and Shareholder Diversification
Lan Gao is allocated 2.5 million shares under Resolution 2, representing a smaller but distinct investor tranche. This allocation, priced at $0.02 per share, requires approval under ASX Listing Rule 7.1. Including individual investors alongside institutional and related parties reflects CurveBeam AI’s strategy to diversify its shareholder base across different investor profiles.
This diversified investor mix may enhance shareholder engagement and market perception by balancing strategic institutional investment with participation from sophisticated individual investors.
Ratification of Previous Share Issue to Shandong WeiYing Intelligent Medical Technology
Resolution 5 seeks shareholder ratification of a prior issuance of 9,876,543 shares to Shandong WeiYing Intelligent Medical Technology Co., Ltd under ASX Listing Rule 7.1A. This ratification is independent of the placement approvals and addresses compliance for a prior equity issuance made under the company’s existing capacity.
The ratification ensures regulatory compliance without impacting the current capital raise. It reflects standard governance procedures and does not indicate irregularities in the original transaction.
Potential Impact of Resolution Failure on Debt Repayment and Operations
Failure to pass Resolutions 1 through 4 will nullify the entire $5 million placement. Without these funds, CurveBeam AI may lack the capital required to meet operational needs and repay a $2.05 million director loan due in October 2027.
The Board has indicated that absent this capital raise, alternative financing options such as further equity or debt may be pursued, though these are not guaranteed. This highlights significant uncertainty regarding the company’s ability to continue operations without shareholder approval of the placement, emphasizing the critical nature of the upcoming vote.
Virtual General Meeting Details and Shareholder Voting Instructions
The general meeting will be held exclusively online on Friday, 21 August 2026 at 09:00am AEST via https://meetnow.global/MXUUHMZ. No physical attendance will be possible. The platform supports live webcast, real-time voting, and shareholder questions during designated times.
Shareholders may vote by attending the virtual meeting or appointing a proxy, with the company recommending appointing the Chair if unable to attend. Proxy forms must be submitted by 09:00am AEST on Wednesday, 19 August 2026. Questions can also be submitted by this deadline, with responses provided per company guidelines.
Deadlines and Participation Support for Shareholders
Advance registration for the meeting opens one hour before commencement. Proxy submissions and question lodgments close at 09:00am AEST on Wednesday, 19 August 2026. Detailed participation and voting instructions are available at https://investors.curvebeamai.com/ and www.investorvote.com.au.
Shareholders needing assistance can contact the share registry at 1300 850 505 (Australia) or +61 3 9415 5000 (international). The Explanatory Memorandum accompanying the Notice of Meeting provides comprehensive details on resolutions and the rationale for the capital raise.
CurveBeam AI’s Market Position and Industry Context
CurveBeam AI Limited operates in the medical imaging technology sector, focusing on AI-powered musculoskeletal imaging solutions that enhance diagnostic accuracy in orthopedics. This sector is part of the broader medical technology and healthcare informatics industry, where AI adoption is rapidly expanding.
The $0.02 per share pricing reflects the company’s current valuation and development stage within a competitive AI-enabled imaging market. The inclusion of international investors such as Intellivision Holdings and Shandong WeiYing indicates CurveBeam AI’s strategy to diversify capital sources geographically and strategically. The musculoskeletal imaging market continues to demand advanced diagnostic technologies, aligning with CurveBeam AI’s innovative AI-driven offerings.
